Suppliers
Contact Us
 GENTAUR Europe BVBAVoortstraat 49, 1910 Kampenhout BELGIUM Tel 0032 16 58 90 45 Fax 0032 16 50 90 45 This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it. |
GENTAUR BULGARIA
53 Iskar Str. 1191 Kokalyane, Sofia
Tel 0035924682280
Fax 0035929830072
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50
Fax 01 43 25 01 60
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
GmbH Marienbongard 20
52062 Aachen Deutschland
Tel (+49) 0241 56 00 99 68
Fax (+49) 0241 56 00 47 88 This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-family: Arial, Tahoma, Verdana, Helvetica; line-height: 15.59375px; ">
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-size: 12px; line-height: 1.3em;">
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531
Fax 020 8445 9411
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR Nederland BV
Kuiper 1
5521 DG Eersel Nederland
Tel 0208-080893
Fax 0497-517897
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93
Fax 02 36 00 65 94
This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR Spain
Tel 0911876558
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
Phone/Fax:
(408) 780-0908
This email address is being protected from spambots. You need JavaScript enabled to view it.
GENPRICE Inc. invoicing/ accounting:
6017 Snell Ave, Suite 357
San Jose, CA. 96123
Serbia, 
Macedonia,
Montenegro, 
Croatia:
Tel 0035929830070
Fax 0035929830072
This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR Romania
Tel 0035929830070
Fax 0035929830072
This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.
GENTAUR Greece
Tel 00302111768494
Fax 0032 16 50 90 45
This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.
Other countries
Luxembourg +35220880274
Schweiz Züri +41435006251
Danmark +4569918806
Österreich +43720880899
Ceská republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Magyarország Budapest +3619980547
Duloxetine reduces painful neuropathy
Antidepressant duloxetine effectively treat peripheral neuropathy induced by chemotherapy showed a phase III clinical study published in the Journal of the American Medical Association.
According to Ellen Smith of the University of Michigan in Ann Arbor, after 5 weeks of treatment, patients receiving duloxetine experienced a significant reduction in morbidity compared with placebo.
Peripheral neuropathy occurs in 20-40% of patients treated with neurotoxic chemotherapy. Such fees are (paclitaxel, docetaxel, etc.)., Vinca alkaloids (vincristine, vinblastine) and platinum compounds (cisplatin, oxaliplatin, etc.).. The condition can persist for years after treatment and greatly reduced quality of life.
Previous studies have shown that inhiborite reuptake of serotonin and norepinephrine (class of antidepressants) have the potential to influence the state. Duloxetine also is known to reduce morbidity and diabetic neuropathy.
In order to clarify the properties of duloxetine, the researchers conducted a randomized, double-blind, placebo-controlled study in 220 patients with stage I or greater sensory neuropathy induced by anti-cancer therapy. All participants were over the age of 25 and assessed their painful 10-ball standard scale, three months after the completion of a chemotherapy course. Half the patients received duloxetine and half - placebo, allocation is done randomly. The soreness was re-assessed after the study.
The end result of the study shows that 5-week treatment with duloxetine significantly reduces morbidity in peripheral neuropathy. This, in turn, enhances the quality of life and employability of patients. The benefits of duloxetine seem greatest for people who have completed chemotherapy with platinum compounds.
The most common side effects of duloxetine documented during the study were fatigue, insomnia and nausea.
Although good design of the study does not include follow-up of patients for an extended period, so it is impossible to tell how lasting are the effects of duloxetine in this indication.
